Health Discovery Corporation Announces Filing of Patent Application Covering Gene Biomarkers for Prostate Disease
SAVANNAH, GA -- 11/23/2004 -- Health Discovery Corporation (OTC BB: HDVY) today announced that it has filed an application in the United States Patent and Trademark Office for patent protection of its latest discoveries relating to diagnosis and treatment of prostate disease. These discoveries include new sets of genetic biomarkers that provide a high degree of accuracy for distinguishing BPH (Benign Prostatic Hyperplasia) from prostate cancer and for distinguishing high-grade prostate cancers from less malignant grades. Biomarkers were also identified for separating BPH from normal prostate with a high degree of accuracy. Claims in the patent application are directed to each new set of biomarkers and their uses in screening, diagnosis and treatment of prostate disease.
The new biomarkers pave the way for possible non- and minimally-invasive tests for screening and diagnosis of prostate disease with greater accuracy and reliability than is currently available with the widely used PSA test. The ability to readily distinguish between the different conditions allows physicians to tailor prostate treatment to a patient’s specific condition, including whether cancer is present and, if so, type or grade of cancer, resulting in significant cost savings by minimizing the need for biopsies and unnecessary or overly aggressive treatments as well as eliminating the adverse effects that invariably accompany unnecessary treatments.
Stephen D. Barnhill, M.D., Chairman and CEO of Health Discovery Corporation, commented, “These new patent applications on our latest discoveries relating to the diagnosis and treatment of prostate disease add significant value to our already impressive patent portfolio.”
Detailed information on this discovery is available in the new Corporate Update Document just released and available on the company web page at www.healthdiscoverycorp.com.
Health Discovery Corporation is a systems biology-oriented biomarker and pathway discovery company, which provides all aspects of First-Phase Biomarker Discovery(SM). Health Discovery Corporation was established to provide pharmaceutical and diagnostic companies with a broad range of analytical and decision support solutions to produce more effective and cost effective diagnostic and drug discovery tools. Founded in September 2003, the Company is headquartered in Savannah, GA. For more information contact: Stephen D. Barnhill, M.D. of Health Discovery Corporation, +1-866-953-9031 or firstname.lastname@example.org.
This news release contains “forward-looking statements” within the meaning of Section 27a of the Securities Acts of 1933 and Section 21E of the Securities Exchange Act of 1934. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct.
- Contact Information
- Stephen D. Barnhill, M.D.
- Health Discovery Corporation
- Contact via E-mail
This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.